Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 298.00
Bid: 296.00
Ask: 299.00
Change: -6.00 (-1.97%)
Spread: 3.00 (1.014%)
Open: 306.00
High: 309.00
Low: 298.00
Prev. Close: 304.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TR-1: Form for notification of major holdings

3 Jul 2019 07:00

RNS Number : 3211E
Hutchison China Meditech Limited
03 July 2019
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Hutchison China MediTech Limited;

Legal Entity Identifier: 2138006X34YDQ6OBYE79

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Prudential plc group of companies

City and country of registered office (if applicable)

London, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

28/06/2019

6. Date on which issuer notified (DD/MM/YYYY):

01/07/2019

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

5.10%

0.00%

5.10%

666,577,450

Position of previous notification (if

applicable)

N/A

N/A

N/A

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

ORD USD0.10

KYG4672N1198

10,899,950

1.63%

SPON ADS

US44842L1035

23,141,235

3.47%

SUBTOTAL 8. A

34,041,185

5.10%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Prudential plc

(Parent Company)

5.10%

0.00%

5.10%

M&G Prudential Limited (wholly owned subsidiary of Prudential plc)

5.10%

0.00%

5.10%

M&G Group Limited

(wholly owned subsidiary of Prudential plc)

5.10%

0.00%

5.10%

M&G Limited

(wholly owned subsidiary of M&G Group Limited)

5.10%

0.00%

5.10%

M&G Investment

Management Limited

(wholly owned subsidiary of M&G Limited)

5.10%

0.00%

5.10%

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

 

 

 

Place of completion

London, United Kingdom

Date of completion

01 July 2019

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLDMGGNKFLGLZG
Date   Source Headline
17th Nov 20207:00 amRNSUS$100m Equity Investment by CPP Investments
5th Nov 20209:00 amRNSChi-Med to Present HMPL-689 Clinical Data at ASH
30th Oct 202012:00 pmRNSChi-Med to Attend Upcoming Conferences
30th Oct 20207:00 amRNSTotal Voting Rights
30th Sep 20207:00 amRNSTotal Voting Rights
21st Sep 20207:00 amRNSSurufatinib Data at ESMO and in Lancet Oncology
17th Sep 202011:45 amRNSSecond Chinese NDA Acceptance for Surufatinib
4th Sep 20207:00 amRNSChi-Med Initiates Global Phase III Trial
3rd Sep 20207:00 amRNSChi-Med Initiates a Phase II Trial
28th Aug 202011:30 amRNSTotal Voting Rights
24th Aug 20207:00 amRNSClinical Data to be Presented at ESMO 2020
12th Aug 202010:30 amRNSGrant of Share Options under Share Option Scheme
10th Aug 20207:00 amRNSSurufatinib Marketing Authorization Application
30th Jul 202012:00 pmRNSInterim Results and Clinical Update
30th Jul 20207:00 amRNSBlock Admission Application
28th Jul 20207:00 amRNSChi-Med & Lilly Collaborate on Elunate in China
28th Jul 20207:00 amRNSSavolitinib NDA Granted Priority Review in China
24th Jul 20207:00 amRNSChi-Med Initiates HMPL-306 Phase I Trial in China
8th Jul 20208:00 amRNSHolding(s) in Company
7th Jul 20208:00 amRNSHolding(s) in Company
7th Jul 20207:00 amRNSNotification of Dilution of Voting Rights
29th Jun 20207:00 amRNSBlocklisting Six Monthly Return
26th Jun 20207:00 amRNSNotice of Results
25th Jun 20207:15 amRNS$100 Million Equity Investment by General Atlantic
18th Jun 20208:15 amRNSFruquintinib Granted US FDA Fast Track Designation
9th Jun 20207:00 amRNSUS$95m Guangzhou Land Compensation Agreement
4th Jun 20207:00 amRNSContinuation of Phase III FRUTIGA Study
2nd Jun 20204:40 pmRNSSecond Price Monitoring Extn
2nd Jun 20204:37 pmRNSPrice Monitoring Extension
1st Jun 20207:00 amRNSChi-Med Plans to Submit US NDA for Surufatinib
29th May 20201:00 pmRNSChi-Med to Discuss Data Presented at ASCO20
29th May 20207:00 amRNSNDA Acceptance in China for Savolitinib
26th May 20207:00 amRNSChi-Med and BeiGene Enter Clinical Collaboration
14th May 20207:00 amRNSClinical Data to be Presented at ASCO20
11th May 20204:41 pmRNSSecond Price Monitoring Extn
11th May 20204:36 pmRNSPrice Monitoring Extension
11th May 20207:00 amRNSChi-Med to Attend Upcoming Investor Conferences
29th Apr 202011:45 amRNSGrant of Share Options under Share Option Scheme
27th Apr 20202:00 pmRNSResult of AGM
22nd Apr 20209:00 amRNSVirtual Presentations of Surufatinib at AACR
21st Apr 202011:30 amRNSGrant of LTIP Awards and Share Options
17th Apr 20207:00 amRNSSurufatinib Granted FDA Fast Track Designations
31st Mar 20207:04 amRNSChina Phase II trial initiation in mesothelioma
25th Mar 20207:00 amRNSAnnual Financial Report
9th Mar 20207:00 amRNSVesting of awards under Long Term Incentive Plan
3rd Mar 20202:18 pmRNSForm-20F Publication
3rd Mar 202012:15 pmRNSFinal Results and Clinical Update
25th Feb 20207:00 amRNSNotice of Results
10th Feb 20207:00 amRNSPhase II Savolitinib / Imfinzi® Combination Data
6th Feb 20204:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.